Anti-TNF-alpha treatment

Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 2002 31(l) 44-5. 

Seriolo B, Paolino S, Sulli A, et al. (2006) Effects of anti-TNF-alpha treatment on hpid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 1069 414-419... 

A 52-year-old woman diagnosed with a seropositive, erosive and nodular RA was followed by several centres for a period of 21 years. Anti-TNF-alpha treatment was commenced due to the failure to control the disease. During the treatment, a serious cellulite developed, which... 

Brandt, J. and Braun, J. 2006. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opinion on Biological Therapy 6(2), 99-107. 

Howard, K. A., Paludan, S. R., Behlkc, M. A., Besenbacher, R, Deleuran, B., Kjems, J. 2009. Chitosan/siRNA nanoparticles-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 17 162-168. 

Inhibition by niacin of inflammatory and oxidative pathways may exert anti-atherosclerotic effects. In cultured human aortic endothelial cells, niacin increased cellular levels of nicotinamide adenine dinucleotide phosphate (reduced) (NADPH) and glutathione, regulators of redox reactions, and reduced production of reactive oxygen species. Niacin inhibited monocyte adhesion through the inhibition of tumour necrosis factor-alpha (TNF-a) induced expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) (Ganji et al. 2009). Persistent increases in plasma adiponectin, an adipokine with anti-inflammatory properties, were found after 6 months of niacin treatment in humans (Linke et al. 2009). 

---